{"id": "test_conflict_001", "question": "With respect to Resuppression, what is the reported difference between patients receiving Nevirapine and those receiving Abacavir?", "evidence": [{"text": "Nineteen of 70 (27%) of individuals (12/46 ABC vs 7/24 NVP; P = .82) with viral load >1000 copies/mL at week 48 experienced resuppression by week 96, indicating no significant difference between treatment groups.", "metadata": {"pmcid": "PMC003952602", "section": "RESULTS", "rank": 1, "study": "DART/NORA 96-week"}}, {"text": "In the NORA substudy at 48 weeks, triple nucleosides (ZDV/3TC/ABC) were associated with significantly higher rates of virologic failure than the NNRTI-based regimen (ZDV/3TC/NVP), suggesting NVP-based regimens achieve better viral suppression outcomes.", "metadata": {"pmcid": "PMC003952602", "section": "INTRODUCTION", "rank": 2, "study": "DART/NORA 48-week"}}, {"text": "A meta-analysis of resuppression studies found that patients on second-line ART had higher resuppression rates than those on first-line ART, regardless of specific drug regimen used.", "metadata": {"pmcid": "PMC006864498", "section": "INTRODUCTION", "rank": 3, "study": "Meta-analysis"}}], "conflict_info": {"type": "outcome_conflict", "description": "Evidence 1 shows no difference at 96 weeks (P=.82), but Evidence 2 suggests NVP-based regimens are superior at 48 weeks. This represents a temporal conflict where short-term and long-term outcomes differ.", "pairs": [{"evidence_idx": [0, 1], "e1_claim": "No significant difference in resuppression (P=.82)", "e2_claim": "NVP-based regimen achieves better viral suppression", "resolution": "Different timepoints (96 weeks vs 48 weeks) and slightly different outcomes (resuppression vs virologic failure)"}], "pico": {"outcome": "Resuppression", "intervention": "Nevirapine", "comparator": "Abacavir"}}, "ground_truth": {"gold_evidence": "Nineteen of 70 (27%) of individuals (12/46 ABC vs 7/24 NVP; P = .82) with viral load >1000 copies/mL at week 48 experienced resuppression by week 96", "gold_label": "no significant difference", "gold_label_code": 0}, "metadata": {"source": "synthetic_for_testing", "difficulty": "medium", "domain": "HIV/AIDS treatment"}}